BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
137.03
+2.74 (+2.04%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close134.29
Open135.60
Bid135.50 x 800
Ask138.89 x 800
Day's Range134.54 - 137.22
52 Week Range87.49 - 236.17
Volume454,026
Avg. Volume672,942
Market Cap7.495B
Beta (3Y Monthly)2.71
PE Ratio (TTM)N/A
EPS (TTM)-10.48
Earnings DateFeb 19, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est179.39
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Report: Exploring Fundamental Drivers Behind Tyson Foods, ElectraMeccanica Vehicles, Cousins Properties, Spirit Aerosystems, bluebird bio, and Yext — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
    Zacks5 days ago

    Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline

    Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
    Zacks6 days ago

    AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma

    AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.

  • Business Wire7 days ago

    bluebird bio Appoints Chip Baird as Chief Financial Officer

    Mr. Baird joins bluebird from Amicus Therapeutics, Inc., where he was the CFO for the past seven years and brings a demonstrated track record of successfully leading companies in all phases of discovery, development and commercialization. Jeff Walsh, who has held various roles over the last eight years at bluebird bio — including chief operating officer and, most recently, chief financial and strategy officer — will assume the new dedicated role of chief strategy officer to drive corporate development and the company’s overall growth strategy.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about bluebird bio Inc.

    bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for BLUE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BLUE totaled $7.82 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea
    Zacks12 days ago

    Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea

    Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.

  • German firm that serves gene therapy biotechs opens Cambridge HQ
    American City Business Journals17 days ago

    German firm that serves gene therapy biotechs opens Cambridge HQ

    Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics and San Francisco-based Denali Therapeutics, and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments.

  • Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y
    Zacks18 days ago

    Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y

    Celgene (CELG) Q4 earnings beat estimates on robust revenues, driven by strong sales of Otezla and Revlimid.

  • ACCESSWIRE18 days ago

    Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...

  • Did bluebird bio, Inc. (NASDAQ:BLUE) Insiders Sell Shares?
    Simply Wall St.21 days ago

    Did bluebird bio, Inc. (NASDAQ:BLUE) Insiders Sell Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...

  • The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
    Zacks25 days ago

    The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

    The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

  • Where Will bluebird bio Be in 5 Years?
    Motley Fool25 days ago

    Where Will bluebird bio Be in 5 Years?

    Looking ahead is the only way to value this biotech.

  • 5 Best Biotech Bets Likely to Outperform Estimates in Q4
    Zacks26 days ago

    5 Best Biotech Bets Likely to Outperform Estimates in Q4

    Let us take a look at five promising biotech stocks for the fourth quarter of 2018.

  • Here's Why CRISPR Therapeutics Stock Fell Today
    Motley Fool27 days ago

    Here's Why CRISPR Therapeutics Stock Fell Today

    A Wall Street analyst isn't too optimistic about the company's lead candidate.

  • GlobeNewswire28 days ago

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. On December 1, 2018, bluebird bio disclosed to the market that the Company had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).” An article posted on December 3, 2018, to Seeking Alpha commented on the announcement, asserting “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” Based on this news, shares of bluebird bio fell more than 5% on the same day.

  • Here's What Pushed bluebird bio Stock Down 44.3% in 2018
    Motley Foollast month

    Here's What Pushed bluebird bio Stock Down 44.3% in 2018

    Disappointing drug launches for expensive, single-application treatments poured water on otherwise impressive progress.

  • 3 Biotech Stocks to Watch in 2019
    Motley Foollast month

    3 Biotech Stocks to Watch in 2019

    Clinical-trial and regulatory-review decisions make these three drug developers worth keeping tabs on this year.

  • ACCESSWIRElast month

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation Against bluebird bio, Inc. (BLUE)

    NEW YORK, NY / ACCESSWIRE / January 11, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers bluebird bio, Inc.("bluebird" or the ''Company") ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / January 11, 2019 / U.S. markets finished in the green on Thursday, however gains were held back by a sharp decline in Macy’s shares that pressured retail stocks lower. The Dow ...

  • Three tech, three biotech companies that are top takeover targets in 2019
    MarketWatchlast month

    Three tech, three biotech companies that are top takeover targets in 2019

    Bristol-Myers Squibb (BMY) last week ponied up $74 billion, a 54% premium, for biotechnology heavyweight Celgene. Big Pharma needs the next generation of treatments to fuel future growth. Another massive purchase was IBM’s (IBM) $33 billion takeover of software firm Red Hat Inc. (RHT) The fact that Big Blue paid a premium of more than 60% in October, one of the worst months for stocks in recent memory, is proof that mega-cap technology companies aren’t afraid to shell out big bucks even amid talk of a tough stock market.

  • The Wall Street Journallast month

    Biotech Proposes Paying for Pricey Drugs by Installment

    A Boston-area biotech says it may have a found a way to handle the expected seven-figure cost of its experimental gene therapy: paying on installment. Bluebird Bio Inc. is developing plans to sell its first gene-replacement therapy, for a rare inherited blood disease, on a five-year installment plan, with each annual payment contingent on its treatment’s continued effectiveness. “Whether it’s just below or considerably below [$2.1 million] is something we need to sort through,” Mr. Leschly said.

  • Celgene (CELG) Provides Guidance for 2019, Updates Pipeline
    Zackslast month

    Celgene (CELG) Provides Guidance for 2019, Updates Pipeline

    Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.

  • bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies
    Business Wirelast month

    bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

    “Access to the Inhibrx sdAb binder technology will allow us to combine the advancements we’ve made with our T cell therapy platform with their sdAb binder technology to generate novel cellular therapies with the potential to help patients in their fight against cancer,” said Philip Gregory, D. Phil., chief scientific officer, bluebird bio. “We are pleased to have formalized our relationship with bluebird bio, allowing us to couple our proprietary sdAb platform with a leading cell therapy platform,” said Brendan Eckelman, Chief Scientific Officer and Executive Vice President of Corporate Strategy of Inhibrx.